MedTrace Logo

Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)

NCT00973102 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-03-19

Study results available
· View outcomes & findings →

Summary

Based on encouraging results from animal studies, the investigators hypothesize that early administration of IV Premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.

Conditions

  • Hemorrhagic Shock

Interventions

DRUG

Premarin IV

One time dose of Premarin IV

DRUG

Placebo

One time dose of placebo.

Sponsors & Collaborators

  • University of Washington

    collaborator OTHER

  • Resuscitation Outcomes Consortium

    collaborator NETWORK

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Rob Schmickers · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-01-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973102 on ClinicalTrials.gov